Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/69911
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Parker, D. | - |
dc.contributor.author | Marino, V. | - |
dc.contributor.author | Sullivan, T. | - |
dc.contributor.author | Ong, J. | - |
dc.contributor.author | Khalafy, J. | - |
dc.contributor.author | Badali, M. | - |
dc.contributor.author | Rimaz, M. | - |
dc.contributor.author | Prager, R. | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Clinical and Experimental Pharmacology and Physiology, 2011; 38(4):203-207 | - |
dc.identifier.issn | 1440-1681 | - |
dc.identifier.issn | 1440-1681 | - |
dc.identifier.uri | http://hdl.handle.net/2440/69911 | - |
dc.description.abstract | 1. GABA(B) autoreceptors are a subclass of GABA(B) receptors that inhibit the release of [(3) H]GABA from GABAergic nerve terminals. Baclofen is an agonist that reduces [(3)H]GABA, whilst the antagonist (+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid (Sch 50911) enhances [(3)H]GABA release in electrically-stimulated rat neocortical brain slices preloaded with [(3)H]GABA. Here, the pharmacological actions of a series of compounds derived from the positive allosteric modulator, 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930), were examined on GABA(B) autoreceptors. 2. The compound, 3-(3,5-ditbutyl-4-hydroxyphenyl)-2,2-dimethyl-1-oximinopropane (compound 2), at 10 μmol/L had little effect on the stimulation-induced overflow of [(3)H]GABA when superfused alone, but when superfused in the presence of baclofen (2 μmol/L) inhibited the overflow of [(3)H]GABA. These effects were reversed by Sch 50911 (10 μmol/L). Although compounds 1-(4-chlorophenyl)-3-(4-hydroxy-3,5-diisopropylphenyl)-2-methyl-1-oximinopropane (compound 1), 1-[(3,5-ditbutyl-4-hydroxyphenyl)methyl]-1-oximinomethylcyclohexane (compound 3), 3-(3,5-ditbutyl-4-hydroxyphenyl)-1,2-diphenyl-1-oximinopropane (compound 4) and 4-(3,5-ditbutyl-4-hydroxyphenyl)-3-methyl-2-oximinobutane (compound 5) (each at 10 μmol/L) tended to reduce the stimulation-induced overflow in the presence of baclofen, an effect reversed by Sch 50911, their status as modulators is not confirmed in the present study. 3. Another derivative, 3-(3,5-ditbutyl-4-hydroxyphenyl)-1-(4-chlorophenyl)-2-methyl-1-oximinopropane (compound 6) (10 μmol/L), acted as an agonist as it inhibited the release of [(3)H]GABA by 32% (EC(50) of 3.3 μmol/L), an effect reversed by Sch 50911 (10 μmol/L). The other compounds, 1-[(3,5-ditbutyl-4-hydroxyphenyl)methyl]-1-methyl-2-oximinocyclohexane (compound 7), 4-(3,5-ditbutyl-4-hydroxyphenyl)-3,3-dimethyl-2-oximinobutane (compound 8) and 4-(4-hydroxy-3,5-diisopropylphenyl)-3,3-dimethyl-2-oximinobutane (compound 9) (each at 10 μmol/L), were inactive. 4. These findings indicate that this series of compounds show different modes of activity at GABA(B) autoreceptors. | - |
dc.description.statementofresponsibility | David AS Parker, Victor Marino, Thomas Sullivan, Jennifer Ong, Jabbar Khalafy, Mohammad Badali, Mehdi Rimaz and Rolf H Prager | - |
dc.language.iso | en | - |
dc.publisher | Wiley-Blackwell Publishing Asia | - |
dc.rights | © 2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd. | - |
dc.source.uri | http://dx.doi.org/10.1111/j.1440-1681.2011.05484.x | - |
dc.subject | autoreceptors | - |
dc.subject | baclofen | - |
dc.subject | GABA | - |
dc.subject | GABAB receptors | - |
dc.subject | rat brain slices. | - |
dc.title | Pharmacological actions of oximino-propofol analogues at GABAB autoreceptors | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1111/j.1440-1681.2011.05484.x | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Ong, J. [0000-0002-0958-460X] | - |
Appears in Collections: | Anaesthesia and Intensive Care publications Aurora harvest |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.